MedTrace Logo

Combined Use of Low-dose Sugammadex Plus Neostigmine Administered for Reversal of Rocuronium

NCT03328312 · Status: UNKNOWN · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 90

Last updated 2017-11-01

No results posted yet for this study

Summary

Reversal of rocuronium-induced neuromuscular block by the combination of low-doses of neostigmine plus sugammadex decreases the cost of anesthetic medications, while maintaining efficacy of reversal in obese patients.

Conditions

  • Incidence of Postoperative Residual Curarization

Interventions

DRUG

Sugammadex

Time period from administration of the reversal agent to recovery of TOFR \>0.9

DRUG

neostigmine+atropine

Number and time of bradycardic episodes (HR\<60 bpm) as well as that of tachycardic episodes (HR\>100 bpm) before tracheal extubation

DRUG

neostigmine+atropine+sugammadex

4\. Time of extubation

Sponsors & Collaborators

  • Iuliu Hatieganu University of Medicine and Pharmacy

    lead OTHER

Principal Investigators

  • Caius Breazu, Md,PhD · Iuliu Hatieganu University of medicine and pharmacy cluj-Napoca

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
16 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-12-01
Primary Completion
2018-03-01
Completion
2018-06-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03328312 on ClinicalTrials.gov